0.80
price down icon1.78%   -0.0145
after-market アフターアワーズ: .78 -0.02 -2.50%
loading

Reviva Pharmaceuticals Holdings Inc (RVPH) 最新ニュース

pulisher
08:01 AM

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference - GlobeNewswire

08:01 AM
pulisher
08:00 AM

Late-Stage CNS Drug Developer Reviva Pharma Reveals New Pipeline Updates at Major Neuroscience Conference - Stock Titan

08:00 AM
pulisher
05:21 AM

RVPH: Open Label Extension Results & Key Opinion Leader Discussion - Yahoo Finance

05:21 AM
pulisher
Jun 04, 2025

Data Readout Positive from Trial of New Schizophrenia Drug - streetwisereports.com

Jun 04, 2025
pulisher
Jun 04, 2025

Reviva Pharmaceuticals (NASDAQ:RVPH) Receives Buy Rating from D. Boral Capital - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Reviva reports positive year-long schizophrenia drug study By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 02, 2025

Reviva Pharmaceuticals Holdings, Inc. Announces Positive Full Dataset for 1-Year Phase 3 Recover Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Reviva Reports Positive Full Dataset For Phase 3 RECOVER OLE Study Of Brilaroxazine In Schizophrenia - Nasdaq

Jun 02, 2025
pulisher
Jun 02, 2025

Reviva reports positive year-long schizophrenia drug study - Investing.com Australia

Jun 02, 2025
pulisher
Jun 02, 2025

Reviva Pharmaceuticals (RVPH) Unveils Promising Phase 3 Brilaroxazine Study Results | RVPH Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Reviva Pharmaceuticals Completes Phase 3 Study for Schizophrenia - TipRanks

Jun 02, 2025
pulisher
Jun 02, 2025

Reviva Pharmaceuticals Reports Positive 1-Year Phase 3 Results for Brilaroxazine in Schizophrenia, Highlighting Efficacy and Safety - Nasdaq

Jun 02, 2025
pulisher
Jun 02, 2025

Reviva Announces Positive Full Dataset for 1-Year Phase 3 - GlobeNewswire

Jun 02, 2025
pulisher
May 31, 2025

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Shares Sold by Millennium Management LLC - Defense World

May 31, 2025
pulisher
May 30, 2025

Reviva Pharmaceuticals Launches $50M At-Market Offering - TipRanks

May 30, 2025
pulisher
May 30, 2025

Reviva Pharmaceuticals Holdings IncEnters Into At Market Issuance Sales AgreementSEC Filing - marketscreener.com

May 30, 2025
pulisher
May 26, 2025

What is Zacks Small Cap’s Estimate for RVPH Q2 Earnings? - Defense World

May 26, 2025
pulisher
May 23, 2025

Roth Capital Issues Positive Forecast for RVPH Earnings - Defense World

May 23, 2025
pulisher
May 22, 2025

D. Boral Capital Lowers Reviva Pharmaceuticals (NASDAQ:RVPH) Price Target to $3.00 - Defense World

May 22, 2025
pulisher
May 20, 2025

Reviva Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks

May 20, 2025
pulisher
May 20, 2025

Reviva stock target cut to $3 on cash concerns, retains Buy rating - Investing.com Australia

May 20, 2025
pulisher
May 20, 2025

Spotify To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Tuesday - NewsBreak: Local News & Alerts

May 20, 2025
pulisher
May 20, 2025

Reviva to Participate in Upcoming Investor Conferences in May 2025 - GlobeNewswire

May 20, 2025
pulisher
May 20, 2025

Late-Stage CNS Drug Developer Reviva Opens Access to Management at Benchmark and Lytham Conferences - Stock Titan

May 20, 2025
pulisher
May 20, 2025

Reviva Pharmaceuticals (RVPH): Analyst Maintains Buy Rating, Low - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Reviva Pharmaceuticals (RVPH) Sees Price Target Reduction Amid Funding Concerns | RVPH Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Reviva Pharmaceuticals (RVPH): Analyst Maintains Buy Rating, Lowers Price Target | RVPH Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Reviva Pharmaceuticals (RVPH) Sees Price Target Reduction Amid F - GuruFocus

May 20, 2025
pulisher
May 16, 2025

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Consensus Rating of “Buy” from Brokerages - Defense World

May 16, 2025
pulisher
May 15, 2025

Reviva Pharmaceuticals (RVPH) Advances Brilaroxazine Program Tow - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Reviva Pharmaceuticals (RVPH) Advances Brilaroxazine Program Towards Approval | RVPH Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights - The Manila Times

May 15, 2025
pulisher
May 15, 2025

Major Milestone: 446 Patients Complete Reviva's Schizophrenia Drug Trial, Full Results Expected Q2 2025 - Stock Titan

May 15, 2025
pulisher
May 13, 2025

Reviva to Participate in the A.G.P. Healthcare Company Showcase - GlobeNewswire

May 13, 2025
pulisher
May 13, 2025

Tower Research Capital LLC TRC Has $48,000 Stock Holdings in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) - Defense World

May 13, 2025
pulisher
May 11, 2025

Reviva Pharmaceuticals (RVPH) Expected to Announce Earnings on Tuesday - Defense World

May 11, 2025
pulisher
May 04, 2025

Short Interest in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Grows By 30.5% - Defense World

May 04, 2025
pulisher
May 03, 2025

Geode Capital Management LLC Grows Position in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) - Defense World

May 03, 2025
pulisher
May 01, 2025

Schizophrenia Market to Witness Significant Growth by 2034 Across 7MM as New Therapies Enter Late-Stage Trials | DelveInsight - GlobeNewswire Inc.

May 01, 2025
pulisher
Apr 29, 2025

Reviva to Participate in the Citizens Life Sciences Conference - GlobeNewswire

Apr 29, 2025
pulisher
Apr 29, 2025

Reviva Pharma CEO Takes Center Stage: Key Updates Coming at Major Life Sciences Conference - Stock Titan

Apr 29, 2025
pulisher
Apr 28, 2025

Gaining Ground: Reviva Pharmaceuticals Holdings Inc (RVPH) Closes Lower at 0.86, Down -4.98 - DWinneX

Apr 28, 2025
pulisher
Apr 28, 2025

Market Update: American Rebel Holdings Inc (AREB) Sees Negative Movement, Closing at 3.85 - DWinneX

Apr 28, 2025
pulisher
Apr 27, 2025

Reviva Pharmaceuticals Holdings, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R) - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 26, 2025

D. Boral Capital Reiterates “Buy” Rating for Reviva Pharmaceuticals (NASDAQ:RVPH) - Defense World

Apr 26, 2025
pulisher
Apr 24, 2025

Reviva Pharmaceuticals Holdings Inc Inc. (RVPH) Price Performance: The Role of Supply and Demand - investchronicle.com

Apr 24, 2025
pulisher
Apr 24, 2025

Reviva to Present Late-Breaking Poster on the RECOVER - GlobeNewswire

Apr 24, 2025
pulisher
Apr 24, 2025

Major Phase 3 Breakthrough: Reviva Unveils 12-Month Schizophrenia Treatment Data at ASCP 2025 - Stock Titan

Apr 24, 2025
pulisher
Apr 24, 2025

Investing in Reviva Pharmaceuticals Holdings Inc (RVPH) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - uspostnews.com

Apr 24, 2025
pulisher
Apr 21, 2025

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Consensus Recommendation of “Buy” by Analysts - Defense World

Apr 21, 2025
pulisher
Apr 19, 2025

Reviva Pharmaceuticals (RVPH) to Release Earnings on Monday - Defense World

Apr 19, 2025
pulisher
Apr 07, 2025

RVPH: M&A Deals Highlight Brilaroxazine Value - MSN

Apr 07, 2025
pulisher
Apr 07, 2025

What is Roth Capital’s Forecast for RVPH Q1 Earnings? - Defense World

Apr 07, 2025
pulisher
Apr 04, 2025

Biopharma Firm Discovers High-Impact CNS Therapy in U.S. With Breakthrough Results - streetwisereports.com

Apr 04, 2025
pulisher
Apr 03, 2025

Reviva Pharmaceuticals Holdings Inc. (RVPH) reports earnings - qz.com

Apr 03, 2025
pulisher
Apr 02, 2025

Reviva Pharmaceuticals (NASDAQ:RVPH) Price Target Lowered to $8.00 at D. Boral Capital - Defense World

Apr 02, 2025
$1.15
price down icon 0.86%
$580.59
price up icon 1.24%
$308.00
price up icon 0.88%
$36.54
price up icon 1.27%
$4.8111
price up icon 1.29%
$483.07
price down icon 0.38%
大文字化:     |  ボリューム (24 時間):